NEW YORK – Clinical genetics firm Blueprint Genetics and rare disease diagnostics company Archimedlife Medical Laboratory said today that they have partnered to offer biochemical testing for rare diseases in North America.
Under the agreement, Blueprint Genetics is licensing Archimedlife's technology and tests to offer biochemical testing at its Seattle laboratory, which also provides next-gen sequencing-based genetic testing. The combined testing services will be available in early 2020.
Financial terms and other details of the partnership were not disclosed.
Archimedlife, based in Vienna, provides biochemical and genetic testing for rare diseases, while Blueprint, headquartered in Helsinki, offers clinical genetic testing. Through their collaboration, the companies plan to make a wide variety of genetic disease testing services available in North America, including clinical mass spectrometry and next-generation sequencing.
"The combined global presence and experience in the field allows us to pursue very interesting opportunities together in the North American rare disease space," said Blueprint Genetics CEO Tommi Lehtonen in a statement.
"Now we have the opportunity, together with a powerful and growing genetic testing company, to serve North American customers," said Archimedlife CEO and Founder David Kasper.